|
Lopez-Galvez R, de la Morena-Barrio ME, Minano A, Pathak M, Marcos C, Emsley J, Caballero T, Lopez-Trascasa M, Vicente V, Corral J, Lopez-Lera A. Thrombin in the Activation of the Fluid Contact Phase in Patients with Hereditary Angioedema Carrying the F12 P.Thr309Lys Variant. Clin Rev Allergy Immunol. 2021 Jun;60(3):357-368. doi: 10.1007/s12016-021-08840-x. Epub 2021 Mar 16. PubMed PMID: 33725261.
AÑO: 2021; IF: 10.817
|
33725261
|
Sanchez-Fuentes A, Rivera-Caravaca JM, Lopez-Galvez R, Marin F, Roldan V. Non-vitamin K Antagonist Oral Anticoagulants and Drug-Food Interactions: Implications for Clinical Practice and Potential Role of Probiotics and Prebiotics. Front Cardiovasc Med. 2022 Jan 17;8:787235. doi: 10.3389/fcvm.2021.787235. eCollection 2021. PubMed PMID: 35111826; PubMed Central PMCID: PMC8801490.
AÑO: 2021; IF: 5.846
|
|
Lopez-Galvez R, Rivera-Caravaca JM. Growth Differentiation Factor 15 in Cardiovascular Diseases: Predicting Bleeding after Cardiac Surgery and Beyond That! Thromb Haemost. 2022 May;122(5):657-660. doi: 10.1055/a-1768-4206. Epub 2022 May 5. No abstract available. PubMed PMID: 35144304.
AÑO: 2022; IF: 6.7
|
|
Roldan V, Martinez-Montesinos L, Lopez-Galvez R, Garcia-Tomas L, Lip GYH, Rivera-Caravaca JM, Marin F. Relation of the 'Atrial Fibrillation Better Care (ABC) Pathway' to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists. J Pers Med. 2022 Mar 17;12(3):487. doi: 10.3390/jpm12030487. PubMed PMID: 35330486; PubMed Central PMCID: PMC8954236.
AÑO: 2022; IF: 3.508
|
|
Lopez-Galvez R, Rivera-Caravaca JM, Anguita Sanchez M, Sanmartin Fernandez M, Rafols C, Perez-Cabeza AI, Baron Esquivias G, Lekuona Goya I, Vazquez Rodriguez JM, Cosin Sales J, Arribas Ynsaurriaga F, Barrios V, Freixa-Pamias R, Marin F. Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study. Eur J Clin Invest. 2022 Sep;52(9):e13788. doi: 10.1111/eci.13788. Epub 2022 Apr 14. PubMed PMID: 35395094.
AÑO: 2022; IF: 5.5
|